These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10404756)

  • 21. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
    Middendorf K; Göhring P; Huehns TY; Seidel D; Steinbeck G; Nikol S
    Am Heart J; 2004 May; 147(5):897-904. PubMed ID: 15131548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of factor V Leiden in healthy Jordanian Arabs.
    Awidi A; Shannak M; Bseiso A; Kailani MA; Kailani MA; Omar N; Anshasi B; Sakarneh N
    Thromb Haemost; 1999 Apr; 81(4):582-4. PubMed ID: 10235443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
    Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR
    Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis.
    Kostka H; Schwarz T; Schellong S; Mix C; Kuhlisch E; Temelkova-Kurktschiev T; Henkel E; Köhler C; Gehrisch S; Siegert G
    Blood Coagul Fibrinolysis; 2003 Jan; 14(1):49-56. PubMed ID: 12544728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.
    Rehak M; Rehak J; Müller M; Faude S; Faude F; Siegemund A; Krcova V; Slavik L; Hasenclever D; Scholz M; Wiedemann P
    Thromb Haemost; 2008 May; 99(5):925-9. PubMed ID: 18449423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
    Holm J; Zöller B; Berntorp E; Erhardt L; Dahlbäck B
    J Intern Med; 1996 Mar; 239(3):221-6. PubMed ID: 8772620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.
    Loew A; Jacob D; Neuhaus P; Riess H
    Transplantation; 2005 May; 79(10):1422-7. PubMed ID: 15912114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss--a possible evolutionary selection mechanism.
    Lindqvist PG; Svensson PJ; Dahlbäck B; Marsál K
    Thromb Haemost; 1998 Jan; 79(1):69-73. PubMed ID: 9459326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis].
    Martínez Ara J; Gómez Rioja R; Riñón C; García Muñoz MS; Ruiz Caravaca ML; Miguel JL
    Nefrologia; 2000; 20(2):139-44. PubMed ID: 10853194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers.
    Morange PE; Aillaud MF; Nicaud V; Henry M; Juhan-Vague I
    Thromb Haemost; 2001 Dec; 86(6):1583-4. PubMed ID: 11776333
    [No Abstract]   [Full Text] [Related]  

  • 31. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
    Tripodi A; Negri B; Bertina RM; Mannucci PM
    Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Association of coagulation factor V, VII gene polymorphisms with coronary heart disease].
    Xu G; Jin GD; Fu GS; Ma J; Shan J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb; 20(1):39-42. PubMed ID: 12579498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
    Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
    Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraindividual consistency of the activated protein C resistance phenotype.
    Tosetto A; Simioni M; Madeo D; Rodeghiero F
    Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):357-8. PubMed ID: 10959717
    [No Abstract]   [Full Text] [Related]  

  • 36. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile.
    Margaglione M; Bossone A; Coalizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di MG
    Thromb Haemost; 2002 Jan; 87(1):32-6. PubMed ID: 11848454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [From gene to disease; risk factors for venous thrombosis: factor V Leiden and prothrombin 20210A].
    Reitsma PH; van de Stolpe A
    Ned Tijdschr Geneeskd; 2001 Sep; 145(38):1843-5. PubMed ID: 11593787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis.
    Ozmen F; Ozmen MM; Ozalp N; Akar N
    Ulus Travma Acil Cerrahi Derg; 2009 Mar; 15(2):113-9. PubMed ID: 19353312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [National evaluation of the diagnosis of activated protein C resistance].
    Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
    Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity.
    Santacroce R; Bossone A; Brancaccio V; Fortina P; Margaglione M
    Thromb Haemost; 2000 Jun; 83(6):963-4. PubMed ID: 10896257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.